Calcium Acetate 667mg (PhosEx)
Brand names: PhosEx, Phoslo
Calcium acetate (PhosEx) is a calcium-based oral phosphate binder used to control hyperphosphataemia in adults with chronic kidney disease, particularly those on dialysis.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
Calcium binds dietary phosphate in the gut to form insoluble calcium phosphate, which is excreted in the faeces, thereby reducing phosphate absorption.
Prescribing in practice
- Must be taken with food (immediately before or with meals) to bind dietary phosphate; taken away from food it provides little phosphate binding and risks hypercalcaemia.
- Provides less elemental calcium per unit of phosphate bound than calcium carbonate, but the total calcium load still contributes to vascular calcification risk.
- Separate administration from oral iron, levothyroxine and many antibiotics (e.g. tetracyclines, quinolones), whose absorption it reduces.
Monitoring
Monitor serum calcium, phosphate and the calcium-phosphate product, with periodic parathyroid hormone review, adjusting therapy to avoid hypercalcaemia.
Counselling the patient
- Take each dose with meals to mop up the phosphate in your food.
- Report symptoms of high calcium such as nausea, constipation, thirst or confusion.
- Do not take indigestion remedies or other calcium supplements without advice.
Evidence & guidelines
Phosphate binders are recommended in CKD-mineral and bone disorder guidance (NICE/KDIGO) to control hyperphosphataemia, with calcium-based binders used cautiously because of calcium loading.
Reference: KDIGO CKD-MBD Guidelines 2017; PhosEx SPC; NICE TA117; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- HE-MACS (History and ECG-Based Manchester ACS Risk Score) · ACS Risk Stratification
- Weight-Based Levothyroxine Dose Calculator · Thyroid
- Number Needed to Treat (NNT) / Number Needed to Harm (NNH) · Evidence-Based Medicine
- Hyperkalaemia Management Algorithm · Electrolyte Disorders
- HIV Opportunistic Infection Risk (CD4-Based) · HIV / Immunodeficiency
- Corrected Calcium · Electrolytes
- Hyperkalaemia Management · UK Kidney Association Guidelines 2020; NICE CKD Guidelines
- Rhabdomyolysis · Renal Association 2018; UpToDate 2024
- Hypocalcaemia (Adult) · Society for Endocrinology
- SIADH (Endocrine Perspective) · European Hyponatraemia Guidelines 2014
- Hepatorenal Syndrome · EASL 2018; ICA 2015
- Acute Kidney Injury (AKI) · KDIGO 2012 / NICE AKI 2019